Azano Pharmaceuticals Inc
Business Identifier: C-reactive protein (CRP) (Az121) and anti-inflammatory derivative of CRP (Az175) for the prevention and reversal of nephritis in patients with systemic lupus erythematosus
Public Profile:
Azano Pharmaceuticals Inc develops C-reactive protein (CRP) (Az121) and an anti-inflammatory derivative of CRP (Az175) for the prevention and reversal of nephritis in patients with systemic lupus erythematosus (SLE). The anti-inflammatory mutant of CRP has FcyR specificity that predicts more selective anti-inflammatory activity than that of natural sequence CRP. Azano Pharma was founded by Puente Partners, LLC, a venture development company in Albuquerque. Azano is structured to have the flexibility to enter into a wide variety of partnerships that will accelerate the commercialization of Az 121 and Az 175. Azano has an exclusive, worldwide license to two issued patents and five patent applications from a long term investigational program led by Terry Du Clos, MD, PhD and Carolyn Mold, PhD at the University of New Mexico Health Sciences Center and the Department of Veterans Affairs Medical Center, Albuquerque. Drs. Du Clos and Mold have demonstrated dramatic prevention and reversal of proteinuria in mouse models of SLE. In addition, they have shown that administration of CRP or CRP-treated macrophages reduces the degree of thrombocytopenia in a mouse model of human immune thrombocytopenia(ITP)

 Synopsis: Awardee Business Condition
Year Founded IP Holdings
Employee Range VC funded?
Revenue Range Private/Public
 Most Recent SBIR Projects
Year Phase Agency Dollars Project Title
Modified C-Reactive Protein For Novel Treatment Of Lupus Nephritis.